THE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.

10/736,535

Applicant

Michael G. Tal

Filed

Michael G. Tal

December 17, 2003

Group Art Unit:

3734

Examiner

Nguyen

Docket No.

TAL-001

Customer No. :

021884

Title

VASCULAR ABLATION APPARATUS AND METHOD

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application.

1. Enclosures accompanying this Information Disclosure Statement are:

1a.	\boxtimes	Form PTO-1449.
1b.	⊠	Copy(ies) of IDS citation(s), except for U.S. Patents and U.S. Patent Application publications for applications filed on or after June 30, 2003.
1.c.		English language copy of a communication(s) from a foreign Patent Office or a PCT International Search Report.
1d.		English language translation (complete, Abstract, or relevant portion(s)) attached to non-English language publications as indicated on the attached PTO Form PTO-1449.
1e.		Explanations of Relevancy of References (ATTACHMENT 1(e), hereto) for providing a concise explanation of non-English publications.
1 f.		List of Copending Applications (ATTACHMENT 1(f), hereto).

	1g.		List of Additional Submitted Documents (ATTACHMENT 1(g), hereto).					
2.	☐ This Information Disclosure Statement is filed under 37 CFR § 1.97(b): (Check either Item 2a or 2b or 2c or 2d)							
	2a. 2b.		Within three months of the filing date of a national application; Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application.					
	2c. 2d.		Before the mailing of a first Office Action on the merits; or Before the mailing of a first Office Action after the filling of a Request for Continued Examination under § 1.114.					
3.	specified in paragraph 2 above but before the mailing date of any of a Final Office Action under § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise closes prosecution in the application, AND							
2. [3a.	⊠	The § 1.97 (e) Statement in Item 5 below is applicable; OR					
	3b.		The \$180.00 fee set forth in 37 CFR § 1.17(p) is: □ enclosed. □ to be charged to Deposit Account No. 01-2221.					
4.	☐ This Information Disclosure Statement is filed under 37 CFR § 1.97(d) after the period specified							
		agraph :	3 above, but on or before payment of the Issue Fee, AND					
	4b.		The \$180.00 fee set forth in 37 CFR § 1.17(p) is: ☐ enclosed.					
			to be charged to Deposit Account No. 01-2221.					
3. ⊠ 3. 3. 3. 3. 3. 4. □	☐ Stater	□ Statement under § 1.97(e) (applicable if Item 3a or 4a is checked) (Check either Item 5a or 5b)						
	Continued Examination under § 1.114. This Information Disclosure Statement is filed under 37 CFR § 1.97(c) after the period specified in paragraph 2 above but before the mailing date of any of a Final Office Action under § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise closes prosecution in the application, AND (Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months) The § 1.97 (e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed. to be charged to Deposit Account No. 01-2221. This Information Disclosure Statement is filed under 37 CFR § 1.97(d) after the period specified in paragraph 3 above, but on or before payment of the Issue Fee, AND 4a. The § 1.97(e) Statement in Item 5 below is applicable; AND The § 180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed. to be charged to Deposit Account No. 01-2221. Statement under § 1.97(e) (applicable if Item 3a or 4a is checked) (Check either Item 5a or 5b) Statement under § 1.97(e) (applicable if Item 3a or 4a is checked) (Check either Item 5a or 5b) In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 5b. In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this							
	5b.	⊠	In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					

6.	Any co cited in for an omitte attache is relie	☐ This is a continuation/division/continuation-in-part application under 37 CFR § 1.53(b). Any copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR § 1.98(d); and similarly any copies of the publications listed on the attached Form PTO-1449 which were not previously cited in the prior application, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have provided herewith.			
7.	☐ This is	a Requ	est for Continued Examination under 37 CFR § 1.114. (Check either Item 7a or 7b)		
	7a.		The Issue Fee has not been paid.		
	7b.	ā	A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed concurrently herewith or has been granted. A Request for Continued Examination under 37 CFR § 1.114, after payment of Issue Fee, is proper in accordance with 37 CFR § 1.114(a), respectively.		
8.	☐ This is	a Supp	lemental Information Disclosure Statement		
			(Check either Item 8a or 8b)		
	8a.		This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can be considered as if properly filed on		
	8b.		This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed		
8a. 8b. 9. 🗆 I			with 37 CFR § 1.98, concise explanation of what is presently understood to be of each non-English publication is:		
			(Check appropriate Items 9a, 9b, 9c and/or 9d)		
	9a.		satisfied for the non-English language publication(s) cited on the enclosed "English language version of the search report or action which indicates the degree of relevance found by the foreign office". (See MPEP § 609, Minimum Requirements for an Information Disclosure Statement, Part A(3): Concise Explanation of the Relevance, 8th Ed., Rev. 2)		
	9Ъ.		set forth in the application.		
	9c.		satisfied for the non-English language publication(s) indicated on the attached Form PTO-1449 as having an English language translation (complete or relevant portion(s)) attached thereto.		
	9d.		enclosed as Attachment 1(e), hereto.		

- 10. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart application or a PCT International Search Report, if submitted herewith). 37 CFR § 1.97(g) and (h).
- 11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account 01-2221.

Respectfully submitted,

Howard N. Flaxman Registration No. 34,595

WELSH & FLAXMAN LLC 2000 Duke Street, Ste. 100 Alexandria, VA 22314 (703) 920-1122

PTO/SB/08A (07-05)

08/17/2008

Considered

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to res Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1

Signature

Translation is attached

/V.N./

spond to a collection of infor	mation unless it contains a va	alid OMB control number.
C	omplete if Known	018
Application Number	10/736,535	4
Filing Date	12/17/2003	JUL 27 2007
First Named Inventor	Michael G. Tal	3 2 7 2007
Art Unit	3734	1
Examiner Name	Nguyen	(A) (S)
Attorney Docket Number	r TAI -001	MOEMAN!

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f Annount)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	$\overline{}$	^{US-} 5,766,191	06/16/1998	Trerotola	
		^{US-} 6,090,118	07/18/2000	McGuckin, Jr.	
		us- 6,602,264	08/05/2003	McGuckin, Jr.	
		^{US-} 6,824,551	11/30/2004	Trerotola	
		^{US-} 7,108,704	09/19/2006	Trerotola	
		^{US-} D450,843	11/20/2001	McGuckin, Jr. et al.	
		US-			

Examiner	Cite	Foreign Patent Document	GN PATENT DOCU Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Poreign Patent Document	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ -Number ⁴ -Kind Code ⁸ (if known)				۲
						Г
	-					_
						_

"EXAMINER." Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's urique citation designation number (potional)." See Kinds Codes of USPTO Palent Documents at www.septo.gov.gov or MPEP 90104. "Either Clinice that issued the document, by the two-letter code (WPO Standard ST.3)," For Japanese patient documents, the indication of the year of the reign of the Emperor must precide the serial number of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is place a check mark far English Indiques."

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPT. The will vary depending upon the individual case. An ordinering the manual of time upon the TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.